While Ozempic is a great choice for many, the best option for obesity management depends on individual factors like health conditions, weight loss goals, and how the body responds to treatment
Study Selection The trials we included met the following criteria: (1) RCTs that compared GLP-1 receptor agonist with a placebo or active control (other antidiabetic drugs or insulin), (2) patients with type 2 diabetes, type 1 diabetes, prediabetes, overweight or obesity, (3) with durations of at least 24 weeks, and (4) reported the occurrence of at least one case of various thyroid disorders as adverse events
Epidemiological literature (LeRoith 2003
This activation, driven by bacterial lipopolysaccharide (LPS), inhibits apoptosis and increases inflammation (195, 196)